DIABETES AS A PROBLEM OF MEDICAL PREVENTION

DOI: https://doi.org/10.29296/25877305-2021-03-02
Download full text PDF
Issue: 
3
Year: 
2021

Professor K. Amlaev, MD Stavropol State Medical University

The relevance of diabetes as a problem of non-communicable diseases has not decreased, but due to the growth of its prevalence has increased significantly. Diabetes, along with obesity and tobacco Smoking, is a leading risk factor for noncommunicable diseases. The article provides data reflecting the epidemiological, pathophysiological, and diagnostic aspects of diabetes mellitus, and describes in detail the recommendations that should be given to patients by doctors of the primary health care network. In a concise form, in the format of a mini-lecture, the main data necessary for the management of this metabolic disease are presented.
Keywords: 
endocrinology
diabetes mellitus
medical prevention

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Young B.A., Lin E., Von Korff M. et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008; 14: 15–23.
  2. da Rocha Fernandes J., Ogurtsova K., Linnenkamp U. et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016; 117: 48–54. DOI: 10.1016/j.diabres.2016.04.016
  3. Bhupathiraju S.N., Hu F.B. Epidemiology of obesity and diabetes and their cardio-vascular complications. Circ Res. 2016; 118: 1723–35. DOI: 10.1161/CIRCRESAHA.115.306825
  4. Boles A.N., Ramesh K., Reddy P.H. Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis. 2017; 1863 (5): 1026–36. DOI: 10.1016/j.bbadis.2017.01.016
  5. Skyler J.S., Bakris G.L., Bonifacio E. et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017; 66: 241. DOI: 10.2337/db16-0806
  6. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. U.S. Department of Health and Human Services, 2014.
  7. Zimmet P., Alberti K.G., Magliano D.J. et al. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016; 12: 616–22. DOI: 10.1038/nrendo.2016.105
  8. Boyle J.P., Thompson T.J., Gregg E.W. et al Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8: 29. DOI: 10.1186/1478-7954-8-29
  9. Schmidt A.M. Highlighting Diabetes – the Epidemic Continues. Arterioscler Thromb Vasc Biol. 2018; 38 (1): e1–e8. DOI: 10.1161/ATVBAHA.117.310221
  10. Haak T., Gölz S., Fritsche A. et al. Therapy of Type 1 Diabetes. Exp Clin Endocrinol Diabetes. 2019; 127: S27–S38. DOI: 10.1055/a-0984-5696
  11. Petersmann A., Müller-Wieland D., Müller U.A. et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019; 127 (S 01): S1–S7. DOI: 10.1055/a-1018-9078
  12. Colstrup M., Mathiesen E.R., Damm P. et al. Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med. 2013; 26: 1682–6. DOI: 10.3109/14767058.2013.794214
  13. Macintosh M.C., Fleming K.M., Bailey J.A. et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ. 2006; 333 (7560): 177. DOI: 10.1136/bmj.38856.692986.AE
  14. Schaefer-Graf U., Napoli A., Nolan C. et al. Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia. 2018; 61 (5): 1012–21. DOI: 10.1007/s00125-018-4545-y
  15. Lemelman M.B. et al. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol. 2018; 45 (1): 41–59. DOI: 10.1016/j.clp.2017.10.006
  16. Greeley S.A.W., John P.M., Winn A.N. et al. The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes. Diabetes Care. 2011; 34: 622–7. DOI: 10.2337/dc10-1616
  17. Triplitt C., Solis-Herrera C., Cersosimo E., et al. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2015; 16: 2819–33. DOI: 10.1517/14656566.2015.1114098
  18. Falciglia M. Causes and consequences of hyperglycemia in critical illness. Curr Opin Clin Nutr Metab Care. 2007; 10: 498–503. DOI: 10.1097/MCO.0b013e3281a3bf0a
  19. Javeed N., Matveyenko A.V. Circadian Etiology of Type 2 Diabetes Mellitus. Physiology. 2018; 33: 138–50. DOI: 10.1152/physiol.00003.2018
  20. Landgraf R., Aberle J., Birkenfeld A. et al. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes. 2019; 127: S73–S92. DOI: 10.1055/a-1018-9106.
  21. Hämäläinen A.-M., Knip M. Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep. 2002; 2: 347–53. DOI: 10.1007/s11892-002-0025-2
  22. Harjutsalo V., Podar T., Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes. 2005; 54: 563–9. DOI: 10.2337/diabetes.54.2.563
  23. Harjutsalo V., Lammi N., Karvonen M. et al. Age at onset of type 1 diabetes in parents and recurrence risk in offspring. Diabetes. 2010; 59: 210–4. DOI: 10.2337/db09-0344
  24. Agardh E., Allebeck P., Hallqvist J. et al. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011; 40: 804–18. DOI: 10.1093/ije/dyr029
  25. Alberti K.G.M.M., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120 (16): 1640–5. DOI: 10.1161/CIRCULATIONAHA.109.192644
  26. Luis M.T.R. LiMa Subclinical Diabetes. Anais da Academia Brasileira de Ciências. 2017; 89 (1 Suppl.): 591–614. DOI: 10.1590/0001-3765201720160394
  27. Törn C., Mueller P.W., Schlosser M. et al. Diabetes antibody standardization program: Evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia. 2008; 51: 846–52. DOI: 10.1007/s00125-008-0967-2
  28. Cryer P.E. The barrier of hypoglycemia in diabetes. Diabetes. 2008; 57: 3169–3176. DOI: 10.2337/db08-1084
  29. American Diabetes Association. Standards of Medical Care in Diabetes – 2017. Diabetes Care. 2017; 40: S4–S5. DOI: 10.2337/dc17-S003
  30. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. URL: http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf
  31. Ziegler R., Neu A. Diabetes in childhood and adolescence – a guideline-based approach to diagnosis, treatment, and follow-up. Dtsch Arztebl Int. 2018; 115: 146–56. DOI: 10.3238/arztebl.2018.0146
  32. Samojlova Ju.G., Rotkank M.A., Zhukova N.G. i dr. Variabel'nost' glikemii u patsientov s saharnym diabetom 1-go tipa: svjaz' s kognitivnoj disfunktsiej i dannymi magnitno-rezonansnyh metodov issledovanija. Problemy endokrinologii. 2018; 64 (5): 286–91 [Samoilova I.G., Rotkank M.A., Zhukova N.G. et al. Variability of glycemia in patients with type 1 diabetes mellitus: the relationship with cognitive dysfunction and the results of magnetic resonance imaging. Problems of Endocrinology. 2018; 64 (5): 286–91 (in Russ.)]. DOI: 10.14341/probl9589
  33. Samojlova Ju.G., Rotkank M.A., Zhukova N.G. i dr. Markery kognitivnyh narushenij i variabel'nost' glikemii u patsientov s saharnym diabetom 1-go tipa. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2018; 118 (4): 48–51 [Samoilova Iu.G., Rotkank M.A., Zhukova N.G. et al. Markers for cognitive impairments and variability of glycaemia in patients with type 1 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118 (4): 48–51 (in Russ.)]. DOI: 10.17116/jnevro20181184148-51
  34. Qing C. The molecular biology in wound healing & non-healing wound. Chin J Traumatol. 2017; 20:189–93. DOI: 10.1016/j.cjtee.2017.06.001
  35. Narayanaswami V., Dwoskin L.P. Obesity: current and potential pharmacotherapeutics and targets. Pharmacol Ther. 2016; 7258: 30194. DOI: 10.1016/j.pharmthera.2016.10.015
  36. Bendas A., Rothe U., Kiess W. et al.: Trends in incidence rates during 1999–2008 and Prevalence in 2008 of childhood type 1 diabetes in Germany. PLoS One. 2015; 10 (7): e0132716.1. DOI: 10.1371/journal.pone.0132716
  37. Adolfsson P., Ziegler R., Hanas R. Continuous subcutaneous insulin infusion: special needs for children. Pediatr Diabetes. 2017; 18: 255–61. DOI: 10.1111/pedi.12491
  38. Cope J.U., Samuels-Reid J.H., Morrison A.E. Pediatric use of insulin pump technology: a retrospective study of adverse events in children ages 1–12 years. J Diabetes Sci Technol. 2012; 6: 1053–9. DOI: 10.1177/193229681200600509
  39. Enander R., Gundevall C., Stromgren A. et al. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2012; 13: 545–51. DOI: 10.1111/j.1399-5448.2012.00883.x
  40. Johnson S.R., Cooper M.N., Jones T.W. et al. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control study. Diabetologia. 2013; 56: 2392–400. DOI: 10.1007/s00125-013-3007-9
  41. Ziegler R., Cavan D.A., Cranston I. et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013; 36: 3613–9. DOI: 10.2337/dc13-0251
  42. Bergenstal R.M., Klonoff D.C., Garg S.K. et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369: 224–32. DOI: 10.1056/NEJMoa1303576
  43. Salas-Salvadó J., Bulló M., Babio N. et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care. 2011; 34: 14–9. DOI: 10.2337/dc10-1288
  44. Nicola D. Guess Dietary Interventions for the Prevention of Type 2 Diabetes in High-Risk Groups: Current State of Evidence and Future Research Needs. Nutrients. 2018; 10 (9): 1245. DOI: 10.3390/nu10091245 Forouhi N.G., Misra A., Mohan V. et al. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ. 2018; 361: k2234. DOI: 10.1136/bmj.k2234
  45. Serra-Majem L., Román-Viñas B., Sanchez-Villegas A. et al. Benefits of the Mediterranean diet: Epidemiological and molecular aspects. Mol Aspects Med. 2019; 67: 1–55. DOI: 10.1016/j.mam.2019.06.001
  46. Taylor R., Al-Mrabeh A., Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 2019; 7 (9): 726–36. DOI: 10.1016/S2213-8587(19)30076-2
  47. Evert A.B., Dennison M., Gardner C.D. et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care. 2019; 42: 731–54. DOI: 10.2337/dci19-0014
  48. American Diabetes Association. Lifestyle management. Sec. 4. In: Standards of Medical Care in Diabetes – 2017. Diabetes Care. 2017; 40 (Suppl. 1): S33–S43. DOI: 10.2337/dc17-S007
  49. American Diabetes Association. Obesity management for treatment of type 2 diabetes. Sec. 7. In: Standards of Medical Care in Diabetes – 2017. Diabetes Care. 2017; 40 (Suppl. 1): S57–S63. DOI: 10.2337/dc17-S010
  50. Lim E.L., Hollingsworth K.G., Aribisala B.S. et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011; 54: 2506–14. DOI: 10.1007/s00125-011-2204-7
  51. Pan A., Yeli Wang Y., Talaei M. et al. Relation of active, passive, and quit ting smoking with incident diabetes: A meta-analysis and systematic review. Lancet Diabetes Endocrinol. 2015; 3 (12): 958–96. DOI: 10.1016/S2213-8587(15)00316-2
  52. Elistratov D.G. «Tireo-Vit» – sekret dolgoletija. Meditsinskaja sestra. 2018; 20 (7): 28–32 [Elistratov D.G. Tireo-vit is the secret of longevity. Meditsinskaya Sestra. 2018; 20 (7): 28–32 (in Russ.)]. DOI: 10.29296/25879979-2018-07-06
  53. Skvortsov V.V., Tumarenko A.V., Vvedenskij S.A. i dr. Aktual'nye voprosy diagnostiki gipertireoza. Meditsinskaja sestra. 2019; 21 (7): 3–7 [Skvortsov V.V., Tumarenko A.V., Vvedensky S.A. et al. Current issues in the diagnosis of hyperthyroidism. Meditsinskaya Sestra. 2019; 21 (7): 3–7 (in Russ.)]. DOI: 10.29296/25879979-2019-07-01
  54. Koldova T., Verbitskaja O., Baranova G. i dr. Kognitivnye rasstrojstva u komorbidnyh patsientov s hronicheskoj ishemiej mozga i gipofunktsiej schitovidnoj zhelezy. Vrach. 2019; 30 (11): 75–9 [Koldova T., Verbitskaya O., Baranova G. et al. Cognitive impairment in comorbid patients with chronic brain ischemia and thyroid hypofunction. Vrach. 2019; 30 (11): 75–9 (in Russ.)]. DOI: 10.29296/25877305-2019-11-18
  55. Sørensen L.E., Jeppesen P.B., Christiansen C.B. Nordic Seaweed and Diabetes Prevention: Exploratory Studies in KK-Ay Mice. Nutrients. 2019; 11 (6): 1435. DOI: 10.3390/nu11061435
  56. Dugan J.A. Exercise recommendations for patients with type 2 diabetes. JAAPA. 2016; 29: 13–8. DOI: 10.1097/01.JAA.0000475460.77476.f6
  57. Lange K., Kleine T., Danne T. Initialschulung für Eltern von Kindern mit Diabetes: Aufwand und Effekte bei Kindern und Eltern. Dtsch Med Wochenschr. 2011; 136: 1106–10. DOI: 10.1055/s-0031-1280518
  58. Lange K., Swift P., Pankowska E. et al. Diabetes education in children and adolescents. Pediatric Diabetes. 2014; 15: 77–85. DOI: 10.1111/pedi.12187
  59. Martin D., Lange K., Sima A. et al. Recommendations for age-appropriate education of children and adolescents with diabetes and their parents in the European Union. Pediatr Diabetes. 2012; 13 (Suppl. 16): 20–8. DOI: 10.1111/j.1399-5448.2012.00909.x